Structure Therapeutics Newsroom

Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts?

Yahoo FinanceNov 27 10:15 ET

U.S. stock market anomaly | Weight loss drug concept stocks are generally up, Eli Lilly (LLY.US) up more than 4%.

On Tuesday, stocks related to weight loss drugs initially rose broadly, with eli lilly and co (LLY.US) up over 4%, scpharmaceuticals (GPCR.US) up over 2%, and novo-nordisk a/s (NVO.US) up over 2%.

Zhitong FinanceNov 26 09:50 ET

White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs

WSJNov 26 05:37 ET

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Simply Wall StNov 25 07:27 ET

Trump Nominates Marty Makary For FDA Commissioner

Barron'sNov 22 22:27 ET

The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.

Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.

wallstreetcnNov 17 07:00 ET

Eli Lilly, Novo Nordisk Shares Slide as Trump Picks RFK Jr. for HHS Post

MarketWatchNov 15 14:25 ET

Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118

Moomoo NewsNov 15 08:31 ET · Ratings

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswireNov 15 08:30 ET

Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Moomoo NewsNov 14 08:35 ET · Ratings

Structure Therapeutics Reports Strong Q3 2024 Results

TipRanksNov 13 23:35 ET

Structure Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 22:32 ET · Announcements

Structure Therapeutics Expects Cash to Fund Operations Through at Least 2027

TipRanksNov 13 16:26 ET

Express News | Structure Therapeutics Inc - Topline Data From Access and Access II Studies Expected Q4 2025

ReutersNov 13 16:23 ET

Express News | Structure Therapeutics Q3 EPS $(0.20), Inline

BenzingaNov 13 16:19 ET

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

SECNov 13 16:17 ET

Express News | Structure Therapeutics Inc: Expects Current Cash, Cash Equivalents & Short-Term Investments to Fund Operations Through at Least 2027

ReutersNov 13 16:13 ET

Express News | Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

ReutersNov 13 16:05 ET

Express News | Structure Therapeutics Inc. Q3 Income From Operations USD -45.836 Million

ReutersNov 13 16:05 ET

Express News | Structure Therapeutics Inc. Q3 Net Income USD -33.977 Million

ReutersNov 13 16:05 ET